UCB SA (OTCMKTS:UCBJF) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of UCB SA (OTCMKTS:UCBJF) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company.

A number of equities research analysts have recently issued reports on UCBJF shares. Jefferies Financial Group raised UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd.

UCB Stock Down 0.9%

OTCMKTS UCBJF opened at $259.10 on Friday. UCB has a 12 month low of $225.65 and a 12 month high of $345.39. The company’s 50 day simple moving average is $282.92 and its 200 day simple moving average is $295.45. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.